KRAS and colorectal carcinoma: In this context TLR3 can serve as an excellent therapeutic target for patients with KRAS mutated CRC as reovirus is more effective in KRAS mutated environment and further down regulation of TLR3 would augment to its efficacy thus being more specifically effective in the KRAS mutated patient cohort.